The use of dipeptidyl peptidase-4 (DPP-4) inhibitors alone or in combination with basal insulin is a safe and an effective treatment option for hospitalized patients with type 2 diabetes, according to the results of a post hoc analysis published in Endocrine Practice.
Insulin is the recommended treatment regimen for hyperglycemia in hospitalized patients with type 2 diabetes and hospital use of oral antidiabetic agents has not been recommended because there are limited data from randomized controlled trials. Researchers completed a post hoc analysis of pooled data from 3 randomized clinical trials to determine the efficacy and safety of DPP-4 inhibitors alone or in combination with basal insulin compared with a basal-bolus insulin regimen in general medicine and surgery patients with type 2 diabetes.
The Sita-Pilot, Sita-Hospital, and Linagliptin-Surgery studies included patients with type 2 diabetes aged 18 to 80 years who were expected to stay in hospital for >24 hours and had blood glucose levels between 140 and 400 mg/dL prior to random treatment assignment. Sitagliptin once daily, alone or in combination with basal insulin, was used in the Sita-Pilot and the Sita-Hospital studies, whereas linagliptin alone was used in the Linagliptin-Surgery study.
In total, 144 patients received a DPP-4 inhibitor alone, 158 received a DPP-4 inhibitor plus basal insulin, and 283 received a basal-bolus regimen. The primary outcome was to determine differences in mean daily blood glucose concentrations between the groups. All groups received correctional doses of rapid-acting insulin for blood glucose levels >140 mg/dL.
The pooled data from the 3 prospective clinical trials showed that hospital treatment with DPP-4 inhibitors alone or in combination with basal insulin resulted in a similar improvement in mean daily blood glucose concentration compared with a basal-bolus regimen (17139 mg/dL, 17142 mg/dL, and 17245 mg/dL, respectively; P =.94). The percentage of patients achieving blood glucose levels within the target range of 70 to 180 mg/dL also did not differ between the groups (63%32%, 60%31%, and 64%28%, respectively; P =.42).
Patients treated with DPP-4 inhibitors alone had fewer hypoglycemic events compared with those treated with DPP-4 inhibitors plus basal insulin or basal-bolus insulin (2%, 9%, and 10%, respectively; P =.004).
Median length of stay was similar with the 3 treatment regimens and was 4.0 days (interquartile range, 3-6 days) with DPP-4 inhibitors alone, 4.0 days (interquartile range, 3-8 days) with a combination of DPP-4 inhibitors plus insulin, and 4.0 days (interquartile range, 3-7 days) with a basal-bolus regimen (P =.12).
The study had several limitations, including the open-label design of the 3 clinical trials and the exclusion of patients admitted to an intensive care unit, those with significant kidney or liver dysfunction or severe hyperglycemia, and those who received a high insulin dose.
[T]his post-hoc analysis supports the use of [DPP-4 inhibitors], alone or in combination with basal insulin in hospitalized patients with [type 2 diabetes] who were treated at home with diet, any combination of oral antidiabetic drugs, or with low-dose insulin therapy, concluded the researchers.
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.
Follow @EndoAdvisor
Reference
Lorenzo-Gonzlez C, Atienza-Snchez E, Reyes-Umpierrez D, et al. Safety and efficacy of DPP4-inhibitors for management of hospitalized general medicine and surgery patients with type 2 diabetes [published online April 27, 2020]. Endocr Pract. doi:10.4158/EP-2019-0481
Originally posted here:
The Role of DPP-4 Inhibitors in Hospitalized Patients With Type 2 Diabetes - Endocrinology Advisor
- Whats Next in Diabetes Care: Innovations and Insights - Beyond Type 1 - April 14th, 2025
- Common Additive Combos in Food And Drinks May Raise Risk of Type 2 Diabetes - ScienceAlert - April 14th, 2025
- Explained: What is Type-5 diabetes? Why the malnutrition-induced condition is back? - Sambad English - April 14th, 2025
- A comprehensive review on the implications of Yogic/ Sattvic diet in reducing inflammation in type 2 diabetes - Nature - April 14th, 2025
- These Food Additives Could Increase Your Risk of Diabetes - VICE - April 14th, 2025
- How Common Food Additives are Linked to Type-2 Diabetes - Discover Magazine - April 14th, 2025
- A conversation about living with Pompe disease and diabetes - Pompe Disease News - April 14th, 2025
- Diabetes in pregnant mothers linked to ADHD and autism risk in children - The Independent - April 14th, 2025
- Study explores potential increased risk between diabetes during pregnancy and ADHD, autism - CBS News - April 14th, 2025
- Possible link between eating food additives and diabetes - KSNV - April 14th, 2025
- GLP-1s Eyed as Key to Managing T1D With Obesity - Medscape - April 14th, 2025
- Want to Lower Your Diabetes Risk? This Kind of Exercise Could Help, Recent Study Says - EatingWell - April 14th, 2025
- Cdk5 inhibitor shows anti-diabetic and neuroprotective effects in type 2 diabetes - BioWorld MedTech - April 14th, 2025
- Researchers uncover a link to autismand it isnt vaccines - Fortune - April 14th, 2025
- Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System - Dexcom - April 14th, 2025
- Heart of the Valley: Hidalgo County man managing his diabetes after losing 60 pounds - KRGV - April 14th, 2025
- Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? - Yahoo Finance - April 14th, 2025
- FGCU Beach Volleyball's Jaci Carpenter not allowing Type 1 diabetes to get in the way - WBBH - April 14th, 2025
- Biomarkers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in Early Detection of Diabetic Foot Ulcers - Cureus - April 14th, 2025
- Unstable Blood Sugar Levels Tied to Higher Erectile Dysfunction Risk in Men with Type 2 Diabetes: Study - Medical Dialogues - April 14th, 2025
- This 'itchy' symptom is an early sign of diabetes that people often miss; know more about it - The Times of India - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - ABC News - February 7th, 2025
- Incidence of type 2 diabetes and metabolic syndrome by Occupation 10-Year follow-up of the Gutenberg Health Study - BMC Public Health - February 7th, 2025
- Abbotts Above the Bias Film Reveals Misconceptions Can Impact Diabetes Care - MultiVu - February 7th, 2025
- Q&A: Diabetes care for the aging population in the digital age - Medical Xpress - February 7th, 2025
- The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes - Nature.com - February 7th, 2025
- Nanoparticle Therapy has Potential to Reprogram the Immune System in Type 1 Diabetes - Managed Healthcare Executive - February 7th, 2025
- Muscle quality index is correlated with insulin resistance and type 2 diabetes mellitus: a cross-sectional population-based study - BMC Public Health - February 7th, 2025
- Assessing type-2 diabetes risk based on the Indian diabetes risk score among adults aged 45 and above in India - Nature.com - February 7th, 2025
- Single-cell atlas of human pancreatic islet and acinar endothelial cells in health and diabetes - Nature.com - February 7th, 2025
- Sugary Drinks Fuel Millions of Diabetes and CVD Cases - Medscape - February 7th, 2025
- 1 in 5 UK adults estimated to have diabetes in new record high - Euronews - February 7th, 2025
- New, increasingly widely used diabetes medication may have additional health benefits for older adults - Medical Xpress - February 7th, 2025
- Patients using diabetes apps can miss critical alerts. Heres how to make sure youre getting them - Canon City Daily Record - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - News-Press Now - February 7th, 2025
- Does wearing a continuous glucose monitor help people without diabetes? We asked experts. - Popular Science - February 7th, 2025
- What is prediabetes and what can you do to stop it? - The Independent - February 7th, 2025
- Diabetes symptoms: 6 high blood sugar warning signs that show on hand and feet - India.com - February 7th, 2025
- The #1 Habit for Better Heart Health If You Have Diabetes, According to Experts - EatingWell - February 7th, 2025
- 'Fix Broken Food System!' Government Urged as Study Says 1 in 5 Brits Affected by Diabetes - Men's Health UK - February 7th, 2025
- World Diabetes Day 2024 - World Health Organization (WHO) - December 6th, 2024
- The WHO Global Diabetes Compact - December 6th, 2024
- Diabetes - World Health Organization (WHO) - December 6th, 2024
- Kumamoto University researchers discover groundbreaking antidiabetic compound - EurekAlert - December 6th, 2024
- Med's David Kaelber comments on GLP-1 agonists, which provide benefits like managing diabetes and weight loss - The Daily | Case Western Reserve... - December 6th, 2024
- Jordan Chiles Is On a Mission To Raise Awareness for Early Type 1 Diabetes Screening - Verywell Health - December 6th, 2024
- There's A Tasty Food That May Reduce Your Risk Of Developing Type 2 Diabetes, Study Shows - HuffPost - December 6th, 2024
- Empagliflozin Linked to Lower Risk of Diabetic Retinopathy Progression - Medpage Today - December 6th, 2024
- GLP-1 Medications Associated with Reduced Likelihood of Dementia Compared to Other Diabetic Meds - Epic Research - December 6th, 2024
- Sanders Slams Greed That Led to Surge in Obesity, Diabetes in US - The Well News - December 6th, 2024
- Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments - The Wall Street Journal - December 6th, 2024
- New Study Teases Out Chocolate and Diabetes Connection - Medpage Today - December 6th, 2024
- Diabetes tool turned wellness trend: Is a glucose monitor right for you? - KARE11.com - December 6th, 2024
- Reporter doesnt have diabetes but wore a glucose monitor anyway. Here's what she learned - CNN - December 6th, 2024
- Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Investors |... - December 6th, 2024
- I dont have diabetes, but I wore a glucose monitor for six weeks. Heres what I learned about food (and anxiety) - CNN - December 6th, 2024
- Higher niacin levels linked to lower cardiovascular risk, but not in those with diabetes - Healio - December 6th, 2024
- This Type Of Chocolate Could Reduce Type 2 Diabetes Risk By 21% - NDTV - December 6th, 2024
- New Study Links Safer BPA Alternatives to Obesity, Diabetes, and Hormone Disruption - SciTechDaily - December 6th, 2024
- Turns Out Dark Chocolate Has a Health Benefit That's Shockingly GreatAnd Totally Unexpected - Well+Good - December 6th, 2024
- Global report on diabetes - World Health Organization (WHO) - October 22nd, 2024
- Ultra-processed food may be particularly harmful for people with diabetes, scientists warn - The Independent - October 22nd, 2024
- New drugs may be able to treat multiple problems beyond diabetes - The Straits Times - October 22nd, 2024
- Best Fruits for Diabetes (and What To Avoid) - Health Essentials - October 22nd, 2024
- Cutting Sugar May Reduce Your Diabetes, Stroke, and Depression Risk - Healthline - October 22nd, 2024
- Can Diabetes Care Teams Improve Patient Outcomes and Value? - Medscape - October 22nd, 2024
- Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD - MD Magazine - October 22nd, 2024
- High expression of CNOT6L contributes to the negative development of type 2 diabetes - Nature.com - October 22nd, 2024
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic... - October 22nd, 2024
- Dental teams could detect undiagnosed diabetes in more than one million people with new care pathway - Nature.com - October 22nd, 2024
- Groundbreaking Innovations in Diabetes Care: Highlights from the 2024 Diabetes Technology Meeting - Beyond Type 1 - October 22nd, 2024
- COVID-19 linked to type 2 diabetes onset in children - Medical Xpress - October 22nd, 2024
- The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel... - October 22nd, 2024
- Does microdosing Ozempic work? What experts are saying about the diabetes drug also used for weight loss - Medical Xpress - October 22nd, 2024
- The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024 - Managed Healthcare Executive - October 22nd, 2024
- The overexpression of human amylin in pancreatic cells facilitate the appearance of amylin aggregates in the kidney contributing to diabetic... - October 22nd, 2024
- RNAO releases updated guidelines for diabetic foot ulcer care - Benefits and Pensions Monitor - October 22nd, 2024
- COVID-19 raises the risk of type 2 diabetes in children, study reveals - News-Medical.Net - October 22nd, 2024
- Semaglutide: What impact does it really have on heart health? - Medical News Today - October 22nd, 2024
- Glucose monitors for diabetes have finally been funded but a chronic workforce shortage will limit the benefits - The Conversation - October 22nd, 2024